Clinical trials
Injection clinical trials
Below are recruiting injection clinical trials, each written for real people, not researchers. We’re tracking 2,096 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07711561RecruitingPhase 1
Cell therapy for cornea swelling after cataract surgery
This trial tests a simple cell treatment for a swollen cornea caused by cataract surgery. It aims to help your cornea become clear again without a full transplant.
Hyderabad, TelanganaAges 18–80 - NCT07275736RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
BeijingAges 18–75 - NCT07479667RecruitingPhase 1
Targeted immune cell therapy for solid tumors after surgery and chemo
This trial tests a new type of immune cell therapy (dendritic cells) that is designed to target specific proteins found on cancer cells. It is for people with certain solid tumors who have already had surgery and at least 4 cycles of standard chemotherapy after surgery.
ShanghaiAges 18–80 - NCT06715085RecruitingPhase 4
PRGF injections for chronic low back pain
This trial tests whether injections of a blood-based treatment called PRGF can help people with long-term low back pain caused by worn discs. It is for those who haven't gotten relief from standard treatments like medication.
Vitoria-Gasteiz, AlavaAges 18 years+ - NCT07508306Recruiting
Blue dye sentinel node mapping for early ovarian cancer
This study is testing a blue dye called Patent Blue to see if it can help surgeons find sentinel lymph nodes (the first nodes cancer might spread to) during surgery for early-stage ovarian cancer. The goal is to reduce the need for more extensive lymph node removal, possibly leading to fewer side effects.
La RabtaAges 18 years+ - NCT06973239Recruiting
Safety and performance of a new bone filler injection
This trial tests Neocement® Inject P, a paste that hardens to fill bone gaps. It might help if you have a bone defect from surgery or injury that does not need structural support.
BarcelosAges 18 years+ - NCT06607757RecruitingPhase 2
Capivasertib plus fulvestrant for high-risk lobular breast cancer
This trial tests adding capivasertib to fulvestrant for women with a certain type of breast cancer (invasive lobular carcinoma) that is hormone-receptor positive and has a high risk of coming back. The treatment is given before surgery to see if it works better than fulvestrant alone.
AugsburgAges 18 years+ - NCT05698459RecruitingPhase 1
Study of a virus treatment delivered into liver arteries
This Phase 1 study tests an oncolytic (tumor-attacking) virus given directly into liver arteries using a catheter. It’s for people with advanced liver cancer who have already tried standard treatments or can’t have them, aiming to assess safety and early anti-cancer activity.
Wuhan, HubeiAges 18–75 - NCT06485154RecruitingPhase 4
Finding the best HIV treatment after PrEP shot failure
This trial is for people who got exposed to HIV despite taking the long-acting PrEP shot (cabotegravir). It tests different pill-based HIV treatment plans to find the best option for them.
Johannesburg, GautengAges 15 years+ - NCT07187908RecruitingPhase 2
Study of Efbemalenograstim Alfa to prevent low white blood cell counts in cancer patients
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
Zhengzhou, HenanAges 18–75 - NCT06474442RecruitingPhase 2
BD111 gene therapy for herpes simplex virus eye infection
This trial tests a new gene therapy called BD111 for people with a herpes simplex virus infection in the cornea (the clear front part of the eye). It aims to see if the treatment is safe and can help clear the virus, possibly improving vision.
Wenzhou, ZhejiangAges 18–70 - NCT06654440RecruitingPhase 2
Testing SHR-A2102 for advanced gynecological cancers
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07043400RecruitingPhase 3
Study comparing two ways to give tislelizumab plus chemo for stomach cancer
This trial compares a shot under the skin versus an IV infusion of tislelizumab, given along with chemotherapy, for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the shot works as well as the IV and may be more convenient.
Chandler, ArizonaAges 18 years+ - NCT06637332RecruitingPhase 4
Comparing two drugs for MRSA bloodstream infections
This trial compares two antibiotics, vancomycin and daptomycin, to see which works better for treating MRSA bacteria in the blood. Patients are randomly assigned to one of the drugs and will be monitored closely for results and side effects.
Blacktown, New South WalesAges 18 years+ - NCT06643754RecruitingPhase 1/Phase 2
Study of a new drug (SHR-3276) for advanced cancers
This trial tests a new drug called SHR-3276 for people with advanced cancers that haven't responded to standard treatments. It aims to see if the drug is safe and works against tumors.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07123545RecruitingPhase 1/Phase 2
Personalized T-cell therapy for advanced liver cancer
This trial tests a personalized treatment using your own immune cells (T-cells) trained to attack specific markers on your liver cancer. It is for people with advanced liver cancer that has worsened after at least two prior treatments and who have tumor tissue available for genetic testing.
Hangzhou, ZhejiangAges 18–75 - NCT06641414RecruitingPhase 3
Lisaftoclax and azacytidine for higher-risk MDS
This trial tests a new drug, lisaftoclax, combined with azacytidine for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if this combination can help control the disease better.
Houston, TexasAges 18 years+ - NCT07472491RecruitingPhase 2/Phase 3
Contrast MRI study for brain, spine, and body cancers
This trial tests a new contrast agent called mangaciclanol for MRI scans of the central nervous system (brain and spine) or body areas like the chest, belly, pelvis, and muscles. You may join if you have known or suspected tumors that need an MRI with contrast, and you're healthy enough to have two contrast MRIs within a short time.
Rochester, MinnesotaAges 18 years+ - NCT07004647Recruiting
MT027 cell injection for advanced peritoneal tumors
This trial tests an experimental cell therapy, MT027, for people with advanced peritoneal tumors that have stopped responding to standard treatments. The goal is to see if MT027 can shrink tumors when injected directly into the abdomen.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06630806RecruitingPhase 1
Study of an injection for relapsed or refractory myeloma
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06461819RecruitingPhase 2
Higher radiation dose for low-to-intermediate prostate cancer
This trial tests if giving a higher dose of radiation in fewer sessions, while using SpaceOAR to protect the rectum, is safe for men with low-to-intermediate risk prostate cancer that hasn't spread.
SeoulAges 20 years+ - NCT07691775RecruitingPhase 1/Phase 2
F18 FBPA PET/CT scan for solid tumors
This trial tests how well a special PET/CT scan with a radioactive tracer called F18 FBPA can detect different types of solid tumors. It aims to see if this scan is safe and effective at finding tumors.
TaipeiAges 18–80 - NCT07028268RecruitingPhase 2
Testing a new drug for bone metastases from solid tumors
This trial tests a new drug called SHR-2017 for people with solid tumors that have spread to the bones. The study aims to see if the drug can help manage pain and other effects of bone metastases.
Guangzhou, GuangdongAges 18 years+ - NCT06255392RecruitingPhase 3
Fluzoparib with apatinib vs chemo for advanced breast cancer
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
Guangzhou, GuangdongAges 18–70
Hear when a new Injection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for injection?
- Yes. Clin2 currently lists 2,096 recruiting injection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a injection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a injection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.